{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-088076","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.151500+00:00","generated_at":"2026-06-12T05:01:13.112168+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Apogee initiates dosing in Phase 1 trial of APG777 ahead of schedule for atopic dermatitis","bullets":["First participants dosed in healthy-volunteer Phase 1 trial of APG777 ahead of initial timeline.","APG777 is a novel half-life extended anti-IL-13 antibody for moderate-to-severe atopic dermatitis.","Preclinical data suggest potential for dosing every two to three months, longer than existing therapies.","Initial subcutaneous pharmacokinetic and safety data from healthy volunteers expected in mid-2024.","Apogee plans to start a randomized Phase 2 trial in moderate-to-severe AD patients in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-088076","json":"https://secwatch.observer/filing/0001104659-23-088076.json","markdown":"https://secwatch.observer/filing/0001104659-23-088076.md","text":"https://secwatch.observer/filing/0001104659-23-088076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465923088076/0001104659-23-088076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465923088076/tm2322937d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T05:01:13.112168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}